Recruiting
Systemic scleroderma
RecruitingStudy on the Safety of T-Guard (Dafsolimab Setaritox, Grisnilimab Setaritox) for Patients with Early Diffuse Cutaneous Systemic Sclerosis
InvestigationalNo placebo
Study on the Safety of T-Guard (Dafsolimab Setaritox, Grisnilimab Setaritox) for Patients with Early Diffuse Cutaneous Systemic Sclerosis
InvestigationalNo placebo
- Disease:Systemic scleroderma
- Substances:Dafsolimab setaritoxGrisnilimab setaritox
Countries:
The Netherlands
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Dafsolimab setaritox